|
| |
Xencor IncorporatedXencor™ is a biotechnology company that is commercializing Protein Design Automation™ (PDA), a proprietary research platform for protein design.
PDA builds on recent groundbreaking advances in computer capabilities and computational chemistry methods to design protein and peptide variants, as well as completely unique protein sequences. PDA produces novel proteins that preserve target functions while modifying selected chemical and biological properties. PDA can rapidly examine vastly more protein sequences than is possible for methods based on genetic screening and selection, resulting in a higher success rate and access to a wider range of novel protein properties.
Xencor's dedicated research facilities include a molecular biology laboratory and a state-of the art computational lab with a parallel supercomputer. Xencor has ongoing collaborations with leading universities, including the California Institute of Technology (Caltech) and the Massachusetts Institute of Technology (MIT).
Xencor is positioned to lead the field of rational biodiscovery by leveraging PDA into new biopharmaceutical and reagents, biomolecule product libraries, databases and proprietary R&D systems. Xencor holds the exclusive worldwide license for PDA technology
| Contact Details: |
| 2585 Nina Street |
| Pasadena |
| CA |
| 91107-3708 |
| United States of America |
| Tel: | 626-744-5750 |
| Fax: | 626-744-5757 |
| Email: | |
| WWW: | www.xencor.com/
|
|
Loading...
|
Recent Publications by Xencor Incorporated: |  |
The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates.
CD19, a B cell-restricted receptor critical for B-cell development, is... | 16th May, 2009
| Xencor,
| Blood. 2009 Apr 16;113(16):3735-43. Epub 2008 Dec 24.
DOI Direct Link |
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
CD19 is a pan B-cell surface receptor expressed from pro-B-cell... | 17th December, 2008
| Xencor, Inc, Monrovia, California 91016, USA.
| Cancer Res. 2008 Oct 1;68(19):8049-57.
DOI Direct Link |
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies.
The humoral immune response requires antigen-specific B cell activation... | 17th December, 2008
| Xencor, Inc., 111 W. Lemon Avenue, Monrovia, CA 91016, USA.
| Mol Immunol. 2008 Sep;45(15):3926-33. Epub 2008 Aug 8.
DOI Direct Link |
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.
The contribution of Fc-mediated effector functions to the therapeutic... | 23rd October, 2008
| Xencor, 111 West Lemon Avenue, Monrovia, CA 91016, USA.
| Mol Cancer Ther. 2008 Aug;7(8):2517-27.
DOI Direct Link |
Phenomena of insulin peak fronting in size exclusion chromatography and strategies to reduce fronting.
Insulin peak fronting in size exclusion chromatography (SEC) results in... | 22nd July, 2008
| Xencor Inc., 111 West Lemon Avenue, Monrovia, CA 91016, USA.
| J Chromatogr A. 2008 May 23;1192(1):121-9. Epub 2008 Mar 22.
DOI Direct Link |
→View more Xencor Incorporated research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 1048 times since April 2007, the link to the organisation's website has been followed 147 times Recent Search Terms used to find this page: xencor cd19 patent | xencor company profile | xencor | PDA novel proteins | (626) 744-5750 | (626) 744-5750 | Blood 2009 113 3735-43 | Blood 2009 113 3735-43 | . Search for more companies in Pasadena Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Xencor Incorporated |
